THE GROUP NEWSLETTER - SWOG

More documents

Recommendations

Info

Manuscripts Page 8 July 3, 2003 — November 12, 2003 Published DECEMBER 2003 THE GROUP N EWSLETTER The publications listed below are those that have been received in published form by the Operations Office Publications Specialist from July 3 through November 12, 2003. C Since Last Newsletter 8710 Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. HB Grossman, RB Natale, CM Tangen, VO Speights, NJ Vogelzang, DL Trump, RW deVere White, MF Sarosdy, DP Wood Jr, D Raghavan, ED Crawford. New England Journal of Medicine 349(9):859-866, 2003. 8819 Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma(MCL) and MCL-BV. S deVos, U Krug, WK Hofmann, GS Pinkus, SH Swerdlow, W Wachsman, TM Grogan, JW Said, HP Koeffler. Diagnostic Molecular Pathology 12(1):35-43, 2003. 8819 Gene expression profile of serial samples of transformed B-cell lymphomas. S de Vos, WK Hofmann, TM Grogan, U Krug, M Schrage, TP Miller, JG Braun, W Wachsman, HP Koeffler, JW Said. Laboratory Investigation 83(2):271- 285, 2003. 8819 The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. A Rosenwald, G Wright, A Wiestner, WC Chan, JM Connors, E Campo, RD Gascoyne, TM Grogan, HK Muller-Hermelink, EB Smeland, M Chiorazzi, JM Giltnane, Em Hurt, H Zhao, L Averett, S Henrickson, L Yang, J Powell, WH Wilson, ES Jaffe, R Simon, RD Klausner, E Montserrat, F Bosch, TC Greiner, DD Weisenburger, WG Sanger, BJ Dave, JC Lynch, J Vose, JO Armitage, RI Fisher, TP Miller, M LeBlanc, G Ott, S Kvaloy, H Holte, J Delabie, LM Staudt. Cancer Cell 3:185-197, 2003. 9003 Prognostic factors and response to fludarabine therapy in Waldenstrom’s Macroglobulinemia: an update of a US Intergroup trial (SWOG S9003). MV Dhodapkar, JL Jacobson, MA Gertz, JJ Crowley, B Barlogie. Seminars in Oncology 30(2):220-225, 2003. 9011 The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. PJ Stiff, JM Unger, SJ Forman, AR McCall, M LeBlanc, AP Nademanee, BJ Bolwell, RI Fisher. Biology of Blood and Marrow Transplantation 9:529-539, 2003. 9041 Adenoma recurrences after resection of colorectal carcinoma: Results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. DZJ Chu, K Chansky, DS Alberts, FL Meyskens Jr, CM Fenoglio-Preiser, SE Rivkin, GM Mills, JK Giguere, GE Goodman, JL Abbruzzese, SM Lippman. Annals of Surgical Oncology 10(8):870-875, 2003. 9208 Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group study 9133. PA Ganz, CM Moinpour, DK Pauler, AB Kornblith, ER Gaynor, SP Balcerzak, GS Gatti, HP Erba, S McCoy, OW Press, RI Fisher. Journal of Clinical Oncology 21(18):3512-3519, 2003. 9217 The influence of finasteride on the development of prostate cancer. IM Thompson, PJ Goodman, CM Tangen, MS Lucia, GJ Miller, LG Ford, MM Lieber, RD Cespedes, JN Atkins, SM Lippman, SM Carlin, A Ryan, CM Szczepanek, JJ Crowley, CA Coltman Jr. New England Journal of Medicine 349:215-224, 2003. 9341 High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. SM Talbot, C Rankin, RN Taub, SP Balcerzak Jr, N Bhoopalam, RA Chapman, LH Baker, EL Middleman, KH Antman. Cancer 98(2):331-336, 2003. 9349 Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma. a phase II study of the Southwest Oncology Group (SWOG 9349). DW Blayney, ML LeBlanc, T Grogan, ER Gaynor, RA Chapman, CH Spiridonidis, SA Taylor, SI Bearman, TP Miller, RI Fisher. Journal of Clinical Oncology 21(13):2466-2473, 2003. S9701 Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. M Markman, PY Liu, S Wilczynski, B Monk, LJ Copeland, RD Alvarez, C Jiang, D Alberts. Journal of Clinical Oncology 21(13):2460-2465, 2003. S9911 A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular Non-Hodgkin’s lymphoma. Southwest Oncology Group protocol S9911. OW Press, JM Unger, RM Braziel, DG Maloney, TP Miller, M LeBlanc, ER Gaynor, SE Rivkin, RI Fisher. Blood 102(5):1606-1612, 2003.
THE GROUP N EWSLETTER Manuscripts Published (Continued) Abstracts Published Since Last Newsletter DECEMBER 2003 Page 9 *9035 HLA D3(7) confers a poor prognosis in intermediate thickness (1.5-4.0 mm) melanoma: serotyping of 553 patients on SWOG 9035. JA Sosman, J Unger, JE Lee, P Liu, L Flaherty, VK Sondak. Proc of the American Society of Clinical Oncology 22:710 (#2856), 2003. 9416 Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (pancoast tumors): mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). VW Rusch, D Giroux, MJ Kraut, J Crowley, M Hazuka, DH Johnson, L Shulman, F Shepherd, D Deschamps, DR Gandara. Proc of the American Society of Clinical Oncology 22:634 (#2548), 2003. *S9628 High dose dexamethasone (Dex) with maintenance Dex/alpha interferon leads to improved survival in patients with primary systemic amyloidosis: results of US Intergroup Trial Southwest Oncology Group (SWOG) S9628. M Dhodapkar, J Jacobson, M Hussein, RA Larson, J Crowley, A Solomon, B Barlogie. Proc of the American Society of Clinical Oncology 22:566 (#2278), 2003. S0000 Challenges of implementing ancillary studies within multi-site clinical trials. T Chay, P Goodman, J Hartline. Controlled Clinical Trials 24(3S) Suppl:182S (#P173), 2003. S0000 Drug distribution challenges in a multi-site clinical trial. A Darke, J Vertrees, P Goodman. Controlled Clinical Trials 24(3S) Suppl:203S (#P217), 2003. S0000 Effectiveness of a media based launch to recruit to a prostate cancer prevention trial. L Minasian, K Smigel-Croker, A Ryan, A Voss, L Cave, E Klein, L Ford. Controlled Clinical Trials 24(3S) Suppl:50S (#14), 2003. S0000 Form and function: PDF+ versus HTML form design. KB Gower, B Kleinman. Controlled Clinical Trials 24(3S) Suppl:188S (#P186), 2003. S0000 Optimizing data collection in a large web-based trial. KB Gower, A Darke. Controlled Clinical Trials 24(3S) Suppl:47S (#10), 2003. S0000 Planning for successful recruitment for cancer trials. K Anderson, J Probstfield, SM Thomas. Controlled Clinical Trials 24(3S) Suppl:102S (#P18), 2003. *Presented The Hope Foundation Platinum Association Drawing Makes Georgia Investigator A Very Happy Guy! Mark R. Keaton, MD, said he and his wife had a “feeling” that they would soon be driving a new Porsche. Even at that, when Dr. Keaton’s name was called during the Platinum Association Prize Drawing, it still took a few moments to sink in. Dr. Keaton is a Medical Oncologist in private practice in August, Georgia. He was given a choice of a 2004 Porsche Boxster or Cayenne SUV — there’s a Cayenne parked in his driveway these days! Andrew D. Jacobs, MD, from Virginia Mason Medical Center in Seattle, and Anthony F. Shields, MD, PhD, Karmanos Cancer Institute in Detroit won roundtrip Southwest Airline tickets and Hyatt accommocations in New Orleans and San Antonio, respectively. The next Porsche drawing for members of the Foundation’s Platinum Association will be held at the 2004 Fall Group Meeting in Kansas City scheduled for October 20-24.
Page 1 and 2: Southwest Oncology Group THE GROUP
Page 3 and 4: THE GROUP N EWSLETTER S9704 - First
Page 5 and 6: THE GROUP N EWSLETTER Cancer Contro
Page 7: THE GROUP N EWSLETTER News from QAR
Page 11 and 12: THE GROUP N EWSLETTER A special PCP
Page 13 and 14: THE GROUP N EWSLETTER CTSU Protocol
Page 15 and 16: THE GROUP N EWSLETTER CRA Plenary S
Page 17 and 18: THE GROUP N EWSLETTER Nurse Oncolog
Page 19 and 20: THE GROUP N EWSLETTER Operations Of
Page 21: THE GROUP N EWSLETTER Mark Your Cal

THE GROUP NEWSLETTER - SWOG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?